Argatroban blocks the activity of thrombin, a key factor in blood clotting. Under an agreement with TBC, SmithKline Beecham has the rights to market and co-develop argatroban in the U.S. and Canada. So drop us a line to let us know what's going on within your organizations. Suggestions for improvements are always welcomed.
Exchange of information adds to the link of knowledge.
Keep our bond strong. The results revealed that fifty out of the 56 patients had complete platelet inhibition. This was a call to action for the medical community to move stroke care to the forefront and to improve clinical outcomes. Congratulations on your success and thanks Justine Bizette. For more inf.